NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3077% above fair value

$12.02−0.50 (-3.99%)

Close on Nov 12, 2026Market cap $412.58MP/E –Yield 0.00%

NeuroPace gross margin

Gross margin is gross profit as a percentage of revenue.

NeuroPace's gross margin for the twelve months ending Sep 30, 2026 was 77.8%. For fiscal 2025 it was 77.2%, against 73.9% the year before. The highest annual figure on record is 77.2% in fiscal 2025.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	77.2%	+3.3
FY2024	Dec 31, 2024	73.9%	+0.4
FY2023	Dec 31, 2023	73.6%	+2.2
FY2022	Dec 31, 2022	71.4%	−2.6
FY2021	Dec 31, 2021	74.0%	+0.4
FY2020	Dec 31, 2020	73.6%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	84.3%	+2.2
Q2 FY2026	Jun 30, 2026	82.8%	−0.3
Q1 FY2026	Mar 31, 2026	81.8%	+4.8
Q4 FY2025	Dec 31, 2025	68.8%	−6.6
Q3 FY2025	Sep 30, 2025	82.1%	+8.9
Q2 FY2025	Jun 30, 2025	83.1%	+9.7
Q1 FY2025	Mar 31, 2025	77.0%	+3.4
Q4 FY2024	Dec 31, 2024	75.4%	+0.2
Q3 FY2024	Sep 30, 2024	73.2%	−1.2
Q2 FY2024	Jun 30, 2024	73.4%	+0.9
Q1 FY2024	Mar 31, 2024	73.6%	+2.0
Q4 FY2023	Dec 31, 2023	75.2%	+6.4
Q3 FY2023	Sep 30, 2023	74.5%	+3.1
Q2 FY2023	Jun 30, 2023	72.5%	−0.7
Q1 FY2023	Mar 31, 2023	71.7%	−0.9
Q4 FY2022	Dec 31, 2022	68.8%	−4.6
Q3 FY2022	Sep 30, 2022	71.4%	−1.2
Q2 FY2022	Jun 30, 2022	73.2%	−0.9
Q1 FY2022	Mar 31, 2022	72.6%	−3.1
Q4 FY2021	Dec 31, 2021	73.4%	−3.0
Q3 FY2021	Sep 30, 2021	72.6%	−2.4
Q2 FY2021	Jun 30, 2021	74.1%	+3.1
Q1 FY2021	Mar 31, 2021	75.7%	+5.0
Q4 FY2020	Dec 31, 2020	76.4%	–
Q3 FY2020	Sep 30, 2020	75.0%	–
Q2 FY2020	Jun 30, 2020	71.0%	–
Q1 FY2020	Mar 31, 2020	70.7%	–